Fig. 1: Prognostic and diagnostic significance of PANDAR for GC patients.

a LncRNA expression profiles were evaluated by an lncRNA expression microarray. Heat map showed different lncRNA expression among samples. ‘Red’ indicates high expression; ‘Green’ indicates low expression. b The expression of PANDAR was demonstrated using northern blotting analysis in paired GC samples. c The expression of PANDAR was demonstrated using real-time PCR analysis in paired GC samples. d High levels of PANDAR in GC tissues correlated with increased tumour size. e High levels of PANDAR in GC tissues correlated with increased TNM stage. f Kaplan−Meier analyses of the overall survival. Patients with a high level of PANDAR expression (above mean; n = 72) were associated with a significantly lower overall survival rate than patients with a low level of PANDAR expression (below mean; n = 74). g ROC plots for the PANDAR discriminating the TNM stage 1/2 group from the healthy group. AUC area under the curve. h ROC plots for the PANDAR discriminating the metastasis group from the non-metastasis group. i ROC plots for the PANDAR discriminating the chemoresistance group from the chemosensitivity group. XELOX regimen: Capecitabine 825–1000 mg/m² bid po d1–14 q3w; Oxaliplatin 130 mg/m² ivgtt d1 q3w